Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 63

1.

Telomerase-based therapies emerging slowly.

Brower V.

J Natl Cancer Inst. 2010 Apr 21;102(8):520-1. doi: 10.1093/jnci/djq145. Epub 2010 Apr 13. No abstract available.

PMID:
20388877
2.

The telomerase antagonist, imetelstat, efficiently targets glioblastoma tumor-initiating cells leading to decreased proliferation and tumor growth.

Marian CO, Cho SK, McEllin BM, Maher EA, Hatanpaa KJ, Madden CJ, Mickey BE, Wright WE, Shay JW, Bachoo RM.

Clin Cancer Res. 2010 Jan 1;16(1):154-63. doi: 10.1158/1078-0432.CCR-09-2850.

3.

The use of novel agents in the treatment of relapsed and refractory multiple myeloma.

Laubach JP, Mahindra A, Mitsiades CS, Schlossman RL, Munshi NC, Ghobrial IM, Carreau N, Hideshima T, Anderson KC, Richardson PG.

Leukemia. 2009 Dec;23(12):2222-32. doi: 10.1038/leu.2009.179. Epub 2009 Sep 10. Review.

4.

Telomerase modulates Wnt signalling by association with target gene chromatin.

Park JI, Venteicher AS, Hong JY, Choi J, Jun S, Shkreli M, Chang W, Meng Z, Cheung P, Ji H, McLaughlin M, Veenstra TD, Nusse R, McCrea PD, Artandi SE.

Nature. 2009 Jul 2;460(7251):66-72. doi: 10.1038/nature08137.

5.

The antiretroviral nucleoside analogue Abacavir reduces cell growth and promotes differentiation of human medulloblastoma cells.

Rossi A, Russo G, Puca A, La Montagna R, Caputo M, Mattioli E, Lopez M, Giordano A, Pentimalli F.

Int J Cancer. 2009 Jul 1;125(1):235-43. doi: 10.1002/ijc.24331.

6.

Human induced pluripotent stem cells free of vector and transgene sequences.

Yu J, Hu K, Smuga-Otto K, Tian S, Stewart R, Slukvin II, Thomson JA.

Science. 2009 May 8;324(5928):797-801. doi: 10.1126/science.1172482. Epub 2009 Mar 26.

7.

Induced pluripotent stem cells from a spinal muscular atrophy patient.

Ebert AD, Yu J, Rose FF Jr, Mattis VB, Lorson CL, Thomson JA, Svendsen CN.

Nature. 2009 Jan 15;457(7227):277-80. doi: 10.1038/nature07677. Epub 2008 Dec 21.

8.

Telomerase inhibitor GRN163L inhibits myeloma cell growth in vitro and in vivo.

Shammas MA, Koley H, Bertheau RC, Neri P, Fulciniti M, Tassone P, Blotta S, Protopopov A, Mitsiades C, Batchu RB, Anderson KC, Chin A, Gryaznov S, Munshi NC.

Leukemia. 2008 Jul;22(7):1410-8. doi: 10.1038/leu.2008.81. Epub 2008 May 1.

9.

Telomerase inhibition by synthetic nucleic acids and chemosensitization in human bladder cancer cell lines.

Kraemer K, Fuessel S, Meye A.

Methods Mol Biol. 2007;405:9-22. doi: 10.1007/978-1-60327-070-0_2.

PMID:
18369813
10.

New therapeutic approach for brain tumors: Intranasal delivery of telomerase inhibitor GRN163.

Hashizume R, Ozawa T, Gryaznov SM, Bollen AW, Lamborn KR, Frey WH 2nd, Deen DF.

Neuro Oncol. 2008 Apr;10(2):112-20. doi: 10.1215/15228517-2007-052. Epub 2008 Feb 20.

11.

The longest telomeres: a general signature of adult stem cell compartments.

Flores I, Canela A, Vera E, Tejera A, Cotsarelis G, Blasco MA.

Genes Dev. 2008 Mar 1;22(5):654-67. doi: 10.1101/gad.451008. Epub 2008 Feb 18.

12.

TERT promotes epithelial proliferation through transcriptional control of a Myc- and Wnt-related developmental program.

Choi J, Southworth LK, Sarin KY, Venteicher AS, Ma W, Chang W, Cheung P, Jun S, Artandi MK, Shah N, Kim SK, Artandi SE.

PLoS Genet. 2008 Jan;4(1):e10. doi: 10.1371/journal.pgen.0040010. Epub 2007 Dec 13.

13.

Clonogenic multiple myeloma progenitors, stem cell properties, and drug resistance.

Matsui W, Wang Q, Barber JP, Brennan S, Smith BD, Borrello I, McNiece I, Lin L, Ambinder RF, Peacock C, Watkins DN, Huff CA, Jones RJ.

Cancer Res. 2008 Jan 1;68(1):190-7. doi: 10.1158/0008-5472.CAN-07-3096.

14.

Loss of beta-catenin impairs the renewal of normal and CML stem cells in vivo.

Zhao C, Blum J, Chen A, Kwon HY, Jung SH, Cook JM, Lagoo A, Reya T.

Cancer Cell. 2007 Dec;12(6):528-41.

15.

Induced pluripotent stem cell lines derived from human somatic cells.

Yu J, Vodyanik MA, Smuga-Otto K, Antosiewicz-Bourget J, Frane JL, Tian S, Nie J, Jonsdottir GA, Ruotti V, Stewart R, Slukvin II, Thomson JA.

Science. 2007 Dec 21;318(5858):1917-20. Epub 2007 Nov 20.

16.

Frequent and specific immunity to the embryonal stem cell-associated antigen SOX2 in patients with monoclonal gammopathy.

Spisek R, Kukreja A, Chen LC, Matthews P, Mazumder A, Vesole D, Jagannath S, Zebroski HA, Simpson AJ, Ritter G, Durie B, Crowley J, Shaughnessy JD Jr, Scanlan MJ, Gure AO, Barlogie B, Dhodapkar MV.

J Exp Med. 2007 Apr 16;204(4):831-40. Epub 2007 Mar 26.

17.

Antiadhesive effects of GRN163L--an oligonucleotide N3'->P5' thio-phosphoramidate targeting telomerase.

Jackson SR, Zhu CH, Paulson V, Watkins L, Dikmen ZG, Gryaznov SM, Wright WE, Shay JW.

Cancer Res. 2007 Feb 1;67(3):1121-9.

18.

Genes and pathways downstream of telomerase in melanoma metastasis.

Bagheri S, Nosrati M, Li S, Fong S, Torabian S, Rangel J, Moore DH, Federman S, Laposa RR, Baehner FL, Sagebiel RW, Cleaver JE, Haqq C, Debs RJ, Blackburn EH, Kashani-Sabet M.

Proc Natl Acad Sci U S A. 2006 Jul 25;103(30):11306-11. Epub 2006 Jul 17.

19.

Telomerase template antagonist GRN163L disrupts telomere maintenance, tumor growth, and metastasis of breast cancer.

Hochreiter AE, Xiao H, Goldblatt EM, Gryaznov SM, Miller KD, Badve S, Sledge GW, Herbert BS.

Clin Cancer Res. 2006 May 15;12(10):3184-92.

20.

Short telomeres, even in the presence of telomerase, limit tissue renewal capacity.

Hao LY, Armanios M, Strong MA, Karim B, Feldser DM, Huso D, Greider CW.

Cell. 2005 Dec 16;123(6):1121-31.

Supplemental Content

Support Center